Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Lymphoma

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Prolymphocytic

Neoplasms by Histologic Type

Hematologic Diseases

Lymphosarcoma

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

All Drugs and Chemicals

Antineoplastic Agents

Immunomodulating Agents

Immunotoxins

Immunotoxin HA22

Immunoconjugates

Immunologic Factors

Immunotoxin therapy

CAT-8015 immunotoxin

Biological therapy

Marie Fuerst, RN, MS

Peter Rosen, MD

Mary Cangany, RN, CCRP

Larry Cripe, MD

NCI Clinical Trials Referral Office

Robert J Kreitman, MD

Krzysztof Jamoziak, MD

Tadeusz Robak, Professor

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to chemotherapy, surgery or radiation therapy.

PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic leukemia or small lymphocytic lymphoma that has not responded to treatment

OUTLINE: Patients receive CAT-8015 IV over 30 minutes on days 1, 3, and 5 followed by rest. Treatment repeats every 4 weeks for up to a total of 10 courses in the absence of dose limiting toxicity, complete response or disease progression. Patients are followed at 1, 3, 6,12,15,18, 21, 24 months following the start of the last treatment cycle.

Cohorts of 3-6 patients each will receive escalating doses of recombinant CAT-8015 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose proceeding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, between16 to 25 new patients will be added to the MTD cohort depending on how well the CAT-8015 is tolerated.

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)

Cambridge Antibody Technology

Leukemia, Hairy Cell

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hairy Cell Leukemia

CAT-8015 Immunotoxin

Sylvia Quesada, RN

Steven E Coutre, MD

Simbi Acharya

Martin Tallman, MD

NCI Clinical Trials Referral

Krzysztof Jamroziak, MD

Claire Dearden, MD

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia(HCL) that has not responded to chemotherapy, surgery or radiation therapy.

PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have hairy cell leukemia (HCL) that has not responded to treatment.

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease	NCT00457860	Leukemia	Immunotoxin the... CAT-8015 immuno... Biological ther...	18 Years -	Cambridge Antibody Technology
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease	NCT00462189	Leukemia Hairy Cell Leuk... HCL	Immunotoxin the... CAT-8015 Immuno... Biological ther...	18 Years -	Cambridge Antibody Technology
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease	NCT00462189	Leukemia Hairy Cell Leuk... HCL	Immunotoxin the... CAT-8015 Immuno... Biological ther...	18 Years -	Cambridge Antibody Technology

Spots Global Cancer Trial Database for ha22

Every month we try and update this database with for ha22 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ha22

Every month we try and update this database with for ha22 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ha22 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.